

## BIOGRAPHICAL SKETCH

Provide the following information for the key personnel and other significant contributors in the order listed on Form Page 2.  
Follow this format for each person. **DO NOT EXCEED FOUR PAGES.**

NAME Oscar Joe Hines	POSITION TITLE		
eRA COMMONS USER NAME HINES2	Professor of Surgery		
<i>EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.)</i>			
INSTITUTION AND LOCATION	DEGREE <i>(if applicable)</i>	YEAR(s)	FIELD OF STUDY
University of Oklahoma	B.S.	1986	Zoology
University of Oklahoma	M.D.	1990	
UCLA		1997	Surgery
Board Certification in Surgery		1998, 2007	

### A. Personal statement.

I have been involved in angiogenesis and pancreatic cancer research for over 10 years and have a clinical practice focused on the surgical management of pancreatic disease. I am an active member of the Jonsson Cancer Center at UCLA, and interact with the National Cancer Institute at a national level. In summary, I have a demonstrated record of successful and productive research projects in areas of pancreatic cancer research and my scientific and administrative expertise and experience have prepared me to lead the proposed research project in collaboration with Co-PIs Dr. Rozengurt and Dr. Eibl.

### B. Positions and Employment

Residency in Surgery	UCLA Department of Surgery	7/90-6/91
Assistant Professor	UCLA Department of Surgery	7/97-5/03
Associate Professor	UCLA Department of Surgery	6/03-6/08
Professor	UCLA Department of Surgery	7/08-present
Associate Chief General Surgery,	UCLA	8/03-present
Director General Surgery Residency Program		4/05-present
Co-Director of the Center for Pancreatic Disease at UCLA		11/05-present

### Activities and Honors

1986	Phi Beta Kappa
1991	Alpha Omega Alpha
1998, 99, 02	Golden Scalpel Award for Teaching Excellence, Assistant Professor, UCLA
2004, 05, 07, 08	Golden Scalpel Award for Teaching Excellence, Associate Professor, UCLA
2008	UCLA School of Medicine – Award for Excellence in Education
2008	Reviewer, NIH SEP/Scientific Review Group 2008/05 ZRG1 IMM-G (02) M
2009, 10	Reviewer, NIH/NCI Tumor Progression and Metastasis
2010	Reviewer, NIH SEP/Scientific Review Group ZRG1 OBT M (02)
2011	Member, NIH/NCI Tumor Progression and Metastasis Study Section

### Professional Organizations

Jonsson Comprehensive Cancer Center, American Surgical Association, Society of Clinical Surgery, Society of University of Surgeons, American College of Surgeons, Association for Academic Surgery, Pancreas Club, American Pancreatic Association, Society of American Gastrointestinal Endoscopic

Surgeons, Society for Surgery of the Alimentary Tract, American Association of Endocrine Surgeons, Societe Internationale de Chirurgie, Pacific Coast Surgical Association, Western Surgical Association

### C. Publications (selected from 129 publications).

1. O'Connell JB, Manunga J, Maggard MA, Ko CY, Tomlinson J, Reber HA, **Hines OJ**. Ampullary cancer: How population-based outcomes compare to academic reports. *Annals of Surgical Oncology* 15:1820-1827 2008.
2. King J, Kazanjian K, Matsumoto J, Reber HA, Yeh MW, **Hines OJ**. Distal pancreatectomy: Incidence of postoperative diabetes. *Journal of Gastrointestinal Surgery* 12(9):1548-1553, 2008.
3. Donahue TR, **Hines OJ**. CXCR2 and RET Single Nucleotide Polymorphisms in Pancreatic Cancer. *World Journal of Surgery* 33(4):710-5, 2009.
4. Büchler P, Reber HA, Tomlinson J, Friess H, Hankinson O, Herr I, **Hines OJ**. Transcriptional regulation of uPAR by HIF-1 is crucial for invasion of pancreatic and liver cancer. *Neoplasia* 11(2):196-209, 2009. PMID: PMC2631144
5. King J, Ng TT, White SC, Cortina G, MD, Reber HA, **Hines OJ**. Pancreatic serous cystadenocarcinoma: a case report and review of the literature. *Journal of Gastrointestinal Surgery* 13(10): 1864-8, 2009. PMID: PMC2759006
6. **Hines OJ**, Reber HA. Pancreatic surgery. *Curr Opin Gastroenterol* 25(5):460-465, 2009.
7. Pham H, Chen M, Li A, King J, Angst E, Dawson DW, Park J, Reber HA, **Hines OJ**, Eibl G. Loss of 15-hydroxyprostaglandin dehydrogenase increases prostaglandin E2 in pancreatic tumors. *Pancreas* 9(3):332-9, 2010. PMID: PMC2859226
8. Manuyakorn A, Paulus R, Farrell J, Dawson NA, Tze S, **Hines OJ**, Reber H, Seligson DB, Horvath S, Kurdistani SK, Guha C, Dawson DW. Cellular histone modification patterns predict prognosis and response to 5-fluorouracil adjuvant therapy in resectable pancreatic adenocarcinoma. *Journal of Clinical Oncology* 10;28(8):1358-65, 2010. PMID: PMC2834495
9. Donahue T, **Hines OJ**. The ZIP4 pathway in pancreatic cancer. *Cancer Biology and Therapy* 29;9(3)243-5, 2010. PMC in Progress
10. Donahue TR, Kazanjian KK, Isacoff WH, Reber HA, **Hines OJ**. Impact of splenectomy on thrombocytopenia, chemotherapy, and survival in patients with unresectable pancreatic cancer. *J Gastrointest Surgery* 14:1012-1018, 2010. PMID: PMC2872015
11. Wasif N, Bentrem DJ, Farrell JJ, Ko CY, **Hines OJ**, Reber HA, Tomlinson JS. Invasive intraductal papillary mucinous neoplasm versus sporadic pancreatic adenocarcinoma: a stage-matched comparison of outcomes. *Cancer* 15;116(14):3369-77, 2010. PMID: PMC2902567
12. King JC, **Hines OJ**. Predicting exocrine insufficiency following pancreatic resection. *Journal of Surgical Research* 164(1):e43-5, 2010. PMID: PMC2957554
13. Li A, King J, Moro J, Sugi MD, Dawson DW, Kaplan J, Li G, Lu X, Strieter RM, Burdick M, Go VLW, Reber HA, Eibl G, **Hines OJ**. Overexpression of CXCL5 is associated with poor survival of patients with pancreatic cancer. *American Journal of Pathology* 178(3):1340-9, 2011. PMID: PMC3069811
14. Li A, Cheng XJ, Moro A, Singh RK, **Hines OJ**, Eibl G. CXCR2-dependent endothelial progenitor cell mobilization in pancreatic cancer growth. *Translational Oncology* 4(1):20-8, 2011. PMID: PMC3026405
15. Takahashi H, Li A, Dawson DW, **Hines OJ**, Reber HA, Eibl G. Cyclooxygenase-2 confers growth advantage to syngeneic pancreatic cancer cells. *Pancreas* 40(3):453-9, 2011. PMID: PMC3077942

## **D. Research Support.**

### **Ongoing research support**

P01 AT003960-01A1 (PI: Go) 11/1/07 – 10/31/12  
NIH NCCAM  
Role: Project 3 Principal Investigator:

“Flavonoids in pancreatic cancer carcinogenesis and angiogenesis.”  
VLW Go Project Principal Investigator. UCLA Center for Excellence in Pancreatic Diseases

R01 CA 123273 (PI: Heaney) 10/1/07 – 9/30/12  
NIH NCI  
Role: Collaborator:  
“Refined Fructose Promotes Pancreatic Cancer Growth.”  
Anthony Heaney, MD, PhD, Principle Investigator

### **Completed Research Support**

R21CA124609 7/1/07 – 6/30/10  
NIH NCI  
Role: Principal Investigator  
“Role of CXCR2 in pancreatic cancer.”

R01 CA104027 03/01/04 - 02/28/08  
NIH NCI  
Role: Co Investigator  
Guido Eibl Principal Investigator  
“The role of COX-2 and PPAR- $\gamma$  in pancreatic cancer”